Physician profile
Medhat E Ismail
NPI 1982665600
$3,078.64
in general payments reported to CMS, 2019-2025
19 companies · $759 in 2025
The $759 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $494 · 2021: $481 · 2022: $153 · 2023: $444 · 2024: $454 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592 · Education: $65.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.86 |
| Education | $65.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,177.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,074.52 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Insmed, INC. | $171.77 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $114.57 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.28 | 2021-2023 | Ofev |
| Merck Sharp & Dohme LLC | $65.30 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $50.96 | 2022-2023 | Dupixent |
| Mylan Specialty L.P. | $47.72 | 2019-2024 | Yupelri |
| Mallinckrodt Enterprises LLC | $39.51 | 2019 | |
| Philips North America LLC | $36.26 | 2019-2020 | |
| Horizon Therapeutics Plc | $29.88 | 2019-2020 | |
| Circassia INC. | $29.12 | 2019-2020 | |
| Verona Pharma, INC. | $29.01 | 2025 | Ohtuvayre |
| Shionogi INC | $19.50 | 2025 | Fetroja |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16.66 | 2024 | Sunosi |
| Amgen INC. | $15.11 | 2025 | Tezspire |
| Harmony Biosciences LLC | $15.06 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Medhat Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.